Abstract:The utility of chemical inhibitors in cytochrome P450 (CYP) reaction phenotyping is highly dependent on their selectivity and potency for their target CYP isoforms. In the present study, 17 inhibitors of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4/5 commonly used in reaction phenotyping were evaluated for their cross-enzyme selectivity in pooled human liver microsomes. The data were evaluated using a statistical desirability analysis to identify (1) inhibitors of superior selectivity for reaction phenotyping and (2) optimal concentrations for each. Among the inhibitors evaluated, α -naphthoflavone, furafylline, sulfaphenazole, tienilic acid, N -benzylnirvanol, and quinidine were most selective, such that their respective target enzymes were inhibited by ~95% without inhibiting any other CYP enzyme by more than 10%. Other commonly employed inhibitors, such as ketoconazole and montelukast, among others, were of insufficient selectivity to yield a concentration that could adequately inhibit their target enzymes without affecting other CYP enzymes. To overcome these shortcomings, an experimental design was developed wherein dose response data from a densely sampled multi-concentration inhibition curve are analyzed by a six-parameter inhibition curve function, allowing accounting of the inhibition of off-target CYP isoforms inhibition and more reliable determination of maximum targeted enzyme inhibition. The approach was exemplified using rosiglitazone N -demethylation, catalyzed by both CYP2C8 and 3A4, and was able to discern the off-target inhibition by ketoconazole and montelukast from the inhibition of the targeted enzyme. This methodology yields more accurate estimates of CYP contributions in reaction phenotyping. SIGNIFICANCE STATEMENT Isoform-selective chemical inhibitors are important tools for identifying and quantifying enzyme contributions as part of a cytochrome P450 (CYP) reaction phenotyping assessment for projecting drug-drug interactions. However, currently employed practices fail to adequately compensate for shortcomings in inhibitor selectivity and the resulting confounding impact on estimates of the CYP enzyme contribution to drug clearance. In this report, we describe a detailed half maximal inhibitory concentration (IC 50 ) study design with 6-parameter modeling approach that yields more accurate estimates of enzyme contribution.

Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential

Development and Full Validation of Six Inhibition Assays for Five Major Cytochrome P450 Enzymes in Human Liver Microsomes Using an Automated 96-Well Microplate Incubation Format and Lc-Ms/Ms Analysis

Investigation of the inhibition of eight major human cytochrome P450 isozymes by a probe substrate cocktail in vitro with emphasis on CYP2E1

A comprehensive assay for nine major cytochrome P450 enzymes activities with 16 probe reactions on human liver microsomes by a single LC/MS/MS run to support reliable in vitro inhibitory drug–drug interaction evaluation

A High-Throughput Inhibition Screening Of Major Human Cytochrome P450 Enzymes Using An In Vitro Cocktail And Liquid Chromatography-Tandem Mass Spectrometry

A sensitive and high-throughput LC-MS/MS method for inhibition assay of seven major cytochrome P450s in human liver microsomes using an in vitro cocktail of probe substrates.

Development of a high throughput cytochrome P450 ligand-binding assay

Rapid Determination of Six Metabolites from Multiple Cytochrome P450 Probe Substrates in Human Liver Microsome by Liquid Chromatography/Mass Spectrometry: Application to High-Throughput Inhibition Screening of Terpenoids

Evaluation of inhibition selectivity for human cytochrome P450 2A enzymes

Establishment of in vitro methods for evaluation of induction and inhibition of human CYP450 enzymes by drugs

Reaction Phenotyping of Low-Turnover Compounds in Long-Term Hepatocyte Cultures Through Persistent Selective Inhibition of Cytochromes P450

Expression and Enzymatic Analysis of the Human Cytochrome CYP1A2 in Saccharomyces cerevisiae

Efficient Substrate Screening and Inhibitor Testing of Human CYP4Z1 Using Permeabilized Recombinant Fission Yeast

A Fluorescence-Based Microplate Assay for High-Throughput Screening and Evaluation of Human UGT Inhibitors.

Functional Expression and Activity Screening of All Human Cytochrome P450 Enzymes in Fission Yeast.

Defining the Selectivity of Chemical Inhibitors Used for Cytochrome P450 Reaction Phenotyping: Overcoming Selectivity Limitations with a Six-Parameter Inhibition Curve-Fitting Approach

Development of a novel cytochrome p450 bioaffinity detection system coupled online to gradient reversed-phase high-performance liquid chromatography

Quantitative Analysis of Cytochrome P450 Isoforms in Human Liver Microsomes by the Combination of Proteomics and Chemical Probe-Based Assay

Computational and in Vitro Studies on the Inhibitory Effects of Herbal Compounds on Human Cytochrome P450 1A2

Determination of CYP1A2 and CYP2D1 Activities in Rat Liver Microsomes and Kinetic Studies Using Ultra Performance Liquid Chromatography Tandem Mass Spectrometry

Absolute Quantification of Cytochrome P450 and Uridinediphosphate Glucuronosyl Transferase Isoforms by Proteomics-based Approach